+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Short-Term Effects of Calcium Antagonists on Renal Haemodynamics in Patients with Chronic Renal Failure

      , ,


      S. Karger AG

      Chronic renal failure, Nifedipine, Nitrendipine, Renal haemodynamics

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Experimental evidence suggests that pharmacological manipulations of glomerular haemodynamics may affect the progression of chronic renal insufficiency and scarring. In this study, we have investigated the short-term (4 weeks) renal haemodynamic effects of nifedipine and nitrendipine (10 mg/thrice daily) in two separate groups of 6 patients with stable chronic renal failure (CRF) (glomerular filtration rate, GFR: 9.7–47.8 ml/min/ 1.73 m<sup>2</sup>). Patients were studied on three occasions: (1) before the administration of the calcium antagonist, (2) after 4 weeks of treatment and (3) 4 weeks after the discontinuation of the drug. Mean arterial pressure fell significantly on nifedipine: from 116.33 ± 12.25 to 107.22 ± 18.67 mm Hg, p < 0.05, and on nitrendipine: from 112.22 ± 10.04 to 102.22 ± 13.77 mm Hg, p < 0.05. There was no significant effect of either calcium antagonist on GFR, effective renal plasma flow (ERPF), proteinuria or natriuresis. Consequently, renal vascular resistance (RVR) fell in both experimental groups, nifedipine: from 51.40 ± 28.77 to 44.97 ± 30 dyn s cm<sup>-5</sup> × 10<sup>3</sup> (mean ± SD), and nitrendipine: from 37.04 + 18.46 to 30.47 ± 15.56 dyn s cm<sup>-5</sup> × 10<sup>3</sup>, p < 0.05. These results show that calcium antagonists reduce systemic blood pressure whilst GFR and ERPF are maintained. The fall in the RVR of patients with CRF treated with calcium antagonists may confer on these agents a therapeutic advantage in the management of progressive renal insufficiency.

          Related collections

          Author and article information

          S. Karger AG
          11 December 2008
          : 58
          : 1
          : 62-67
          Sheffield Kidney Institute, Northern General Hospital, Sheffield, UK
          186380 Nephron 1991;58:62–67
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Original Paper


          Comment on this article